Preventing GLP-1-Associated Facial Aging: An Anatomy-Driven Risk Stratification Model and Prevention Algorithm in the “Ozempic Face” Era

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed metabolic care but are increasingly associated with rapid, region-specific facial volume loss, commonly referred to as “Ozempic face.” Current literature remains descriptive and largely focused on late-stage correction.

Objective

To propose a conceptual, anatomy-driven framework for early identification and prevention of GLP-1 RAs-associated facial aging.

Methods

This manuscript presents a hypothesis-generating model developed through integration of facial aging biomechanics, emerging literature on GLP-1 RAs-associated changes, and clinical pattern recognition.

Results

We introduce a risk-stratification model based on anatomical phenotype and a four-phase conceptual prevention algorithm aligned with weight-loss kinetics. The framework incorporates early intervention strategies, clinical “off-ramps,” and patient-specific modifiers to guide anticipatory management.

Conclusion

This conceptual model proposes a shift from reactive correction to preventive, anatomy-based management of GLP-1 RAs-associated facial changes. Future studies are needed to validate and refine this framework.

Level of Evidence V

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.